QHSLab, Inc. is leading the way in assisting independent practices to embrace reimbursable non-face-to-face digital health tools for efficient clinical decision support and patient care coordination.

QHSLab, Inc. (the “Company”) (OTCQB: USAQ), a company focused on providing clinicians with tools to leverage proactive, value-based healthcare solutions through emerging digital health and point of care technologies, today announced the launch of its proprietary Post-COVID Condition Health Habits digital health tool for screening primary care patients potentially suffering from a “long COVID” or “post-COVID” conditions.

QHSLab, Inc. (OTCQB: USAQ), a company focused on providing clinicians with tools to leverage proactive, value-based healthcare solutions through emerging point of care technologies, today announced a strategic alliance with Medical License Factory, LLC, a prominent physician licensing and management services organization, for its AllergiEnd® allergy diagnostic and allergen immunotherapy products and clinical decision support digital health services.

Recent headlines undoubtedly caused concern for investors across all industries. However, at QHSLab, Inc., we are confident in our ability to weather the market volatility with our sound fundamental point of care and digital healthcare business focus. Since our inception we have been focused on achieving earnings and positive cash flow and have steadily moved towards those goals. Despite these challenging times, we have been generating growing revenue over the past six quarters and see continuing progress, while keeping our expenses down.

The delivery of healthcare is changing. The recent HIMSS State of Healthcare summit in Orlando, Florida, highlights the changing landscape since the onset of the COVID pandemic in 2020. The key takeaway stated succinctly by a panelist is this: "[Digital transformation] is no longer an option; it's a mandate.” Now more than ever, patients are demanding comprehensive care for their investment in healthcare. With insurance premiums and deductibles at all-time highs, value and positive peer reviews are some of the most critical points of consideration when deciding to book an appointment with a provider. In addition, referrals are crucial for sustaining practices, and there's no better referral than word-of-mouth.

QHSLab, Inc. (OTCQB: USAQ) a company focused on providing clinicians with tools to leverage proactive, value-based healthcare solutions through emerging point of care technologies, projects a new $90 million annual addressable market for the Company’s latest product, the Allergy Quick Test, branded AllergiQT™.

QHSLab, Inc. (OTCQB: USAQ) a company focused on providing clinicians with tools to leverage proactive, value-based healthcare solutions through emerging digital health and point of care technologies, announces an update to the Company’s corporate presentation highlighting the Company’s 2021 achievements and future plans underway.

USA Equities Corp (USAQ: OTCQB) has announced that the company is now named QHSLab, Inc. after receiving FINRA approval. The name change signals an exciting moment of growth for the company that provides digital health solutions and point of care diagnostic tests to primary care physicians. The company's flagship product, QHSLab, has garnered brand recognition, and after reviewing strong 2021 earnings, company leadership decided to make QHSLab, Inc. the company's name.

USA Equities Corp (OTCQB: USAQ), a digital healthcare company focused on providing clinicians with artificial intelligence tools to leverage proactive, value-based healthcare solutions through the use of emerging digital and point of care technologies, announced its financial results for the fourth quarter and full-year 2021.

The delivery of healthcare is changing. Last week at the HIMSS State of Healthcare summit in Orlando, Florida, highlighted the changing landscape since the onset of the COVID pandemic in 2020. The key takeaway stated succinctly by a panelist is this: "[Digital transformation] is no longer an option; it's a mandate.”

USA Equities Corp is proud to announce the newest digital medicine and point of care clinical decision-making tools that will be brought into the market throughout 2022. The company's flagship product, QHSLab, is a clinical decision support system combining intelligent patient health risk assessments with medical guideline-based care coordination recommendations for medical providers at the point of care and in non-face-to-face settings. QHSLab was designed to address high-cost acuity and chronic health conditions with low-cost interventions that reimburse busy primary care physicians.

On behalf of the entire USAQ team, we thank you for your investment in the #FutureofMedicine. We're proud of the tremendous strides made in 2021 and look forward to continuing the momentum and surpassing expectations throughout 2022 and beyond.

USA Equities Corp. (OTCQB: USAQ), a company focused on providing clinicians with tools to leverage proactive value-based healthcare solutions through the use of emerging digital and point of care technologies, recently found additional scientific validation for its digital medicine platform - QHSLab.

USA Equities Corp. (OTCQB: USAQ), a company focused on providing clinicians with tools to leverage value-based healthcare solutions through the use of emerging digital and point of care technologies, today introduced its proprietary AllergiQT™ - Quick Test focused on the allergy testing market and targeting independent primary care physicians in the United States.

USA Equities Corp. (OTCQB: USAQ), a company focused on providing clinicians with tools to profit from value-based healthcare solutions through the use of emerging digital technologies, today announced the launch of its proprietary Q-Scale, or Quality of Life, digital medicine assessment tool for screening patients potentially suffering from mental and emotional health-related issues.

USA Equities Corp. (OTCQB: USAQ), a company focused on value-based healthcare solutions and physician-directed digital medicine today, announced second-quarter financial results for the period ended June 30, 2021. The strong, sequential growth on several fronts aligned with the Company’s July 15 pre-announced results.

In this article, Troy Grogan, CEO of USA Equities Corp. (OTCQB: USAQ), talks about five focal points that drive USAQ's business model and growth trajectory. First, USAQ's business structure generates recurring revenue for both USAQ and its physician clients. At the same time, the Company's point of care and remote patient monitoring technology meets the increasing demand for virtual care in post-pandemic healthcare.

“We had a very strong second quarter and delivered on our prior guidance for both revenue growth and gross margin expansion sequentially compared to the first quarter of 2021. Our growth reflected increased sales of allergy diagnostic kits and immunotherapy treatments, expanding our customer base, and strong execution by our team. We leveraged our deep applications expertise and industry relationships. Our targeted solutions and compelling customer value proposition are clearly resonating with independent medical practitioners. In addition, we remain disciplined allocators of capital with the increase in our second quarter cash balance allowing us to further opportunistically invest in driving our growth strategy and anticipate continued revenue growth in the third quarter,” said Troy Grogan, CEO of USA Equities Corp.

“Today’s announcement is further evidence of our continued progress and momentum as we expand our independent medical provider practice network. The growing interest in AllergiEnd®’s allergy diagnostic services and allergen immunotherapy products reflects the attractiveness of our value-based tools to proactively address chronic disease, provide preventive care as well as enable the broad market of general practitioner physicians to broaden their practices and revenue base,” said Troy Grogan, CEO of USA Equities Corp.

“We made excellent progress executing on our financial and strategic priorities in the first quarter of 2021,” stated USAQ Chief Executive Officer Troy Grogan. “On a sequential basis, our revenue more than doubled to approximately $304,000, while gross margin improved 370 basis points to 43.9%. This growth is due to increased sales of allergy diagnostic kits and immunotherapy treatments as well as expansion of our customer base We also saw continued momentum in April, and currently expect an increase in revenue and gross margin in the second quarter of 2021.”